May 22, 2026

Universität Heidelberg Successful with Application for Collaborative Research Centre

Universität Heidelberg Successful with Application for Collaborative Research Centre

DFG funds extended CRC with approximately 17.4 million euros

Heidelberg University has been successful in the latest approval round of the German Research Foundation (DFG) with a grant application for a major research consortium: The Collaborative Research Centre “Molecular Circuits of Heart Disease” (CRC 1550), based at the Medical Faculty Heidelberg, is entering a second funding period. It focuses on how inherited and acquired causes – for instance, genetic variations, environmental influences, stress or lifestyle – give rise to heart disease. Prof. Dr Johannes Backs, Director of the Institute for Experimental Cardiology at Heidelberg University Hospital, will continue to serve as spokesperson during the second funding phase. The DFG is funding the CRC for four years with a total of approximately 17.4 million euros. 

The aim of CRC 1550 “Molecular Circuits of Heart Disease” is to decode the complex interplay of risk constellations and trigger factors of heart disease. The research is based on the assumption that every phenotype of heart disease is caused by specific molecular circuits which in some cases overlap with the circuits of other manifestations. In order to locate these overlaps and hubs in the origin of disease, the scientists combine both data from experimental model systems and patient data with findings from systems biology. Multi-omics approaches are intended to enable an integrative analysis of the varying molecular levels. In this way, the researchers discover which “switches” could serve as new targets for tailored therapies. Besides scientists from the Medical Faculty Heidelberg, the research studies also involve experts from the Medical Faculty Mannheim and the new Helmholtz Institute for Translational AngioCardioScience (HI-TAC) at Heidelberg University. Also participating are researchers from the European Molecular Biology Laboratory (EMBL), the German Cancer Research Center (DKFZ) and the University of Göttingen.

Scientists from Heidelberg University are, moreover, involved in two more Collaborative Research Centres that have now been extended. One is the Goethe University Frankfurt-based CRC 1531 “Damage Control by the Stroma-Vascular Compartment”, which is entering its second funding period. Researchers from the Medical Faculty Heidelberg are likewise participating in CRC/TRR 237 “Nucleic Acid Immunity”, which is coordinated at LMU Munich and entering its third funding period.

Our latest News

discover more
Vaccine Against Brain Tumors Shows Promising Long-Term Results

Vaccine Against Brain Tumors Shows Promising Long-Term Results

A novel vaccination strategy against certain malignant brain tumors could fundamentally improve treatment for patients. Researchers from the German Cancer Research Center (DKFZ), Mannheim University Medical Center, Heidelberg University Hospital, and numerous partner institutions* have published encouraging long-term results from a clinical trial involving a vaccine that activates the immune system against a common genetic […]

VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering

VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering

The next-generation platform integrates VectorBuilder’s regulatory-compliant gene delivery technology with MaxCyte’s clinically validated electroporation platform to enable robust, scalable, and reliable clinical-grade cell engineering. Chicago, IL & Rockville, MD – June 23, 2026 – VectorBuilder, a global leader in gene delivery technologies and CDMO services, and MaxCyte, a leading, cell-engineering company providing enabling platform technologies to […]

LEEI-Platform eFIT is Available to Industry and Research

LEEI-Platform eFIT is Available to Industry and Research

KyooBe Tech is making its innovative vaccine development platform available to industry and research partners:Enabling faster and scalable vaccine production using Low-Energy Electron Irradiation (LEEI). Flexible Vaccine Manufacturing for Emerging Infectious Diseases Recent infectious disease events—from hantavirus outbreaks and meningitis cases to recurring disease outbreaks in livestock farming—highlight the need for flexibly scalable vaccine manufacturing […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp